For the Inventor, By the Inventor

Enter assignee name

Culver City, CA, United States of America

Immunitybio, Inc.

USPTO Granted Patents = 62

CIPO Patents = 1

EPO Patents = 12

Trademarks = 14

Forward Citations = 77

Loading Chart...

Loading Chart...

55 inventors (with patents filed for the assignee):

Patrick Soon-Shiong (25 out of 475 patents)

Hans G Klingemann (22 out of 47 patents)

Laurent H Boissel (18 out of 36 patents)

4. Hing C Wong (11 out of 110 patents)

5. Barry J Simon (8 out of 18 patents)

6. Nicholas James Witchey (8 out of 160 patents)

7. John Zachary Sanborn (6 out of 63 patents)

8. Luna Witchey (6 out of 6 patents)

9. Kayvan R Niazi (6 out of 99 patents)

10. Shahrooz Rabizadeh (5 out of 86 patents)

11. Rohit Duggal (5 out of 5 patents)

12. Ranjeet Sinha (4 out of 4 patents)

13. Abhijit Dandapat (4 out of 5 patents)

14. Himani Chinnapen (4 out of 4 patents)

15. John H Lee (3 out of 13 patents)

Core Competencies:

Chimeric Antigen Receptor

NK Cells

Immunotherapy

Vaccines

Neuroinflammation

T-cell Memory

Bioprocessing

Tumor Microenvironment

SARS-CoV-2

Adenoviral Vectors

Mononuclear Cells

Protein Production

62 patents: Sort by Forward Citations

1. 12681020 - Compositions and Methods for NK-92 Cells Expressing Native CD16 (2026-07-14),

2. 12653874 - Nant cancer vaccine (2026-06-16),

3. 12594323 - METHODS OF REDUCING NEUROINFLAMMATION (2026-04-07),

4. 12558408 - Intratumorally injected yeast vaccine (2026-02-24),

5. 12516112 - SINGLE-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF (2026-01-06),

6. 12509494 - MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF (2025-12-30),

7. 12503680 - Methods and systems for cell bed formation during bioprocessing (2025-12-23),

8. 12497462 - ANTI-CD26 PROTEINS AND USES THEREOF (2025-12-16),

9. 12492377 - MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC (2025-12-09),

10. 12491201 - Maximizing T-cell memory and compositions and methods therefor (2025-12-09),

11. 12479899 - MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF (2025-11-25),

12. 12459981 - Primary NK CAR constructs and methods (2025-11-04),

13. 12456240 - Fiducial localization with sparse annotations (2025-10-28),

14. 12448638 - Enzyme based system for production of messenger RNA with increased transfection efficiency (2025-10-21),

15. 12435122 - Fc-epsilon CAR (2025-10-07),

ImmunityBio, Inc. is a leading biotechnology company focused on developing next-generation immunotherapies to improve the treatment of cancer and infectious diseases. Combining expertise in immunology, bioinformatics, and nanotechnology, ImmunityBio aims to revolutionize the field of immunotherapy by developing innovative therapies that can activate and direct the immune system to combat diseases effectively. With a robust pipeline of novel drugs, ImmunityBio is dedicated to advancing the understanding and application of immunotherapy to provide better outcomes for patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Immunitybio, Inc.

62 Patents

#7 in Culver City, CA

#1,367 in California

#5,840 in US

#11,755 in the World

Culver City, CA, United States of America

Immunitybio, Inc.

Forward Citations = 77

55 inventors:

Patrick Soon-Shiong (25 out of 475 patents)

Hans G Klingemann (22 out of 47 patents)

Laurent H Boissel (18 out of 36 patents)

4. Hing C Wong (11 out of 110 patents)

5. Barry J Simon (8 out of 18 patents)

Please report any incorrect information to [email protected]

Loading…